Risks and Benefits of Glioblastoma Resection in Older Adults : A Retrospective Austrian Multicenter Study

Show full item record



Permalink

http://hdl.handle.net/10138/310728

Citation

Schwartz , C , Romagna , A , Stefanits , H , Zimmermann , G , Ladisich , B , Geiger , P , Rechberger , J , Winkler , S , Weiss , L , Fastner , G , Trinka , E , Weis , S , Spiegl-Kreinecker , S , Steinbacher , J , McCoy , M , Johannes , T , Gruber , A , Jahromi , B R , Niemelä , M , Winkler , P A & Thon , N 2020 , ' Risks and Benefits of Glioblastoma Resection in Older Adults : A Retrospective Austrian Multicenter Study ' , World Neurosurgery , vol. 133 , pp. E583-E591 . https://doi.org/10.1016/j.wneu.2019.09.097

Title: Risks and Benefits of Glioblastoma Resection in Older Adults : A Retrospective Austrian Multicenter Study
Author: Schwartz, Christoph; Romagna, Alexander; Stefanits, Harald; Zimmermann, Georg; Ladisich, Barbara; Geiger, Philipp; Rechberger, Julian; Winkler, Sophie; Weiss, Lukas; Fastner, Gerd; Trinka, Eugen; Weis, Serge; Spiegl-Kreinecker, Sabine; Steinbacher, Juergen; McCoy, Mark; Johannes, Trenkler; Gruber, Andreas; Jahromi, Behnam Rezai; Niemelä, Mika; Winkler, Peter A.; Thon, Niklas
Contributor: University of Helsinki, HUS Neurocenter
University of Helsinki, Department of Neurosciences
Date: 2020-01
Language: eng
Number of pages: 9
Belongs to series: World Neurosurgery
ISSN: 1878-8750
URI: http://hdl.handle.net/10138/310728
Abstract: OBJECTIVE: To assess the prognostic profile, clinical outcome, treatment-associated morbidity, and treatment burden of elderly patients with glioblastoma (GBM) undergoing microsurgical tumor resection as part of contemporary treatment algorithms. METHODS: We retrospectively identified patients with GBM >= 65 years of age who were treated by resection at 2 neuro-oncology centers. Survival was assessed by Kaplan-Meier analyses; log-rank tests identified prognostic factors. RESULTS: The study population included 160 patients (mean age, 73.1 +/- 5.1 years), and the median contrastenhancing tumor volume was 31.0 cm(3). Biomarker analyses revealed 0(6)-methylguanine-DNA methyltransferase-promoter methylation in 62.7% and wild-type isocitrate dehydrogenase in 97.5% of tumors. The median extent of resection (EOR) was 92.3%, surgical complications were noted in 10.0% of patients, and the median postoperative hospitalization period was 8 days. Most patients (60.0%) received adjuvant radio-/chemotherapy. The overall treatment-associated morbidity was 30.6%. The median progression-free and overall survival were 5A months (95% confidence interval [Cl], 4.6-6.4 months) and 10.0 months (95% CI, 7.9-11.7 months). The strongest predictors for favorable outcome were patient age = 80% (P = 0.0179), postoperative modified Rankin Scale score CONCLUSIONS: Clinical outcome for elderly patients with GBM remains limited. Nonetheless, the observed treatment-associated morbidity and treatment burden were moderate in the patients, and patient age and performance status remained the strongest predictors for survival. The risks and benefits of tumor resection in the age of biomarker-adjusted treatment concepts require further prospective evaluation.
Subject: Adjuvant treatment
Biomarker
Elderly
Glioblastoma multiforme
Outcome
Resection
Treatment-associated morbidity
NEWLY-DIAGNOSED GLIOBLASTOMA
ELDERLY-PATIENTS
SURVIVAL OUTCOMES
EUROPEAN ASSOCIATION
RESPONSE ASSESSMENT
RADIATION-THERAPY
MALIGNANT GLIOMA
TEMOZOLOMIDE
MULTIFORME
RADIOTHERAPY
3112 Neurosciences
3124 Neurology and psychiatry
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1878875019325288_main.pdf 675.2Kb PDF View/Open
1_s2.0_S1878875019325288_main.pdf 1.262Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record